Hofland J, Timmerman M A, de Herder W W, van Schaik R H N, de Krijger R R, de Jong F H
Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, the Netherlands.
Clin Endocrinol (Oxf). 2006 Dec;65(6):792-9. doi: 10.1111/j.1365-2265.2006.02668.x.
The growth and differentiation factors activin and inhibin can affect tumour formation and steroid production in the adrenal cortex. These factors bind to type I (Alk-4), type II (ActRIIA, ActRIIB) and type III (betaglycan) receptors or to the activin-binding protein follistatin. Expression of these activin-related mRNAs was measured in different types of adrenocortical tissues and tumours to study the relationship with tumorigenesis.
Quantitative expression of activin-related mRNAs was investigated in patient adrenocortical samples.
Twenty-eight human adrenocortical samples from normal and hyperplastic adrenals and from adrenocortical adenomas and carcinomas were collected after surgery for study purposes.
Using quantitative reverse transcription polymerase chain reaction (RT-PCR), we investigated the expression of inhibin alpha-, betaA- and betaB-subunits, follistatin, betaglycan, ActRIIA, ActRIIB and Alk-4 in the adrenocortical tissues. The expression of cytochrome P450c17 (CYP17) mRNA was also measured to investigate its association with inhibin and activin subunit expression.
All genes studied were expressed in all tissues, with the exception of the inhibin alpha-subunit in one hyperplastic adrenal and three adrenocortical carcinomas. Expression of inhibin betaA-subunit, follistatin, betaglycan, ActRIIA, ActRIIB and CYP17 differed between nontumorous adrenals and carcinomas.
These differences, together with correlation analysis, indicate parallel regulation of the expression of CYP17, the inhibin alpha-subunit, ActRIIA, ActRIIB, betaglycan and follistatin. We conclude that the expression of activin and inhibin subunits, receptors and binding proteins is affected by tumour formation in the adrenal gland and may play a role in tumorigenesis.
生长分化因子激活素和抑制素可影响肾上腺皮质肿瘤的形成及类固醇生成。这些这些因子与I型(Alk-4)、II型(ActRIIA、ActRIIB)和III型(β-聚糖)受体或激活素结合蛋白卵泡抑素结合。检测这些激活素相关mRNA在不同类型肾上腺皮质组织和肿瘤中的表达,以研究其与肿瘤发生的关系。
研究患者肾上腺皮质样本中激活素相关mRNA的定量表达。
收集28例人肾上腺皮质样本,这些样本来自正常及增生的肾上腺、肾上腺皮质腺瘤和癌,均为术后获取用于研究。
采用定量逆转录聚合酶链反应(RT-PCR),检测肾上腺皮质组织中抑制素α亚基、βA亚基和βB亚基、卵泡抑素、β-聚糖、ActRIIA、ActRIIB和Alk-4的表达。同时检测细胞色素P450c17(CYP17)mRNA的表达,以研究其与抑制素和激活素亚基表达的相关性。
除1例增生肾上腺和3例肾上腺皮质癌中未检测到抑制素α亚基外,所有研究基因均在所有组织中表达。非肿瘤性肾上腺与癌组织中抑制素βA亚基、卵泡抑素、β-聚糖、ActRIIA、ActRIIB和CYP17的表达存在差异。
这些差异以及相关性分析表明,CYP17、抑制素α亚基、ActRIIA、ActRIIB、β-聚糖和卵泡抑素的表达存在平行调控。我们得出结论,激活素和抑制素亚基、受体及结合蛋白的表达受肾上腺肿瘤形成的影响,可能在肿瘤发生中发挥作用。